You are viewing an expired study

Dallas, Texas 75390

  • Bipolar Disorder


This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.

Study summary:

Bipolar II disorder (BDII) is a serious condition characterized by depressive and hypomanic episodes. The disability and suicide risk associated with BDII is equal to bipolar I disorder. However, there are no clinical trials for BDII, nor is the treatment of BDII addressed in current treatment guidelines. Data suggest that Li and LTG may be effective treatment options for BDII. This study will determine the safety, effectiveness, and tolerability of the two drugs in people with BDII. Participants in this study will be randomly assigned to receive either Li or LTG for 16 weeks. Participants will be assessed every 2 weeks. One week after study completion, participants will have a follow-up visit. Measures of depression, mania, quality of life, functioning, and participant satisfaction will be taken.


Inclusion Criteria: - Current diagnosis of bipolar II disorder Exclusion Criteria: - Use of lithium or lamotrigine - Intolerance to lithium or lamotrigine - Substance abuse or dependence within the last month - Suicidal thoughts - Unstable medical conditions - Pregnancy or breast-feeding - Stable on current medications - Use of fluoxetine (Prozac) within 2 weeks of study - Require an antipsychotic medication - Do not speak or read English



Primary Contact:

Principal Investigator
Trisha Suppes, MD, PhD
Stanford University

Backup Contact:


Location Contact:

Dallas, Texas 75390
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.